Kromek : secures £5m bio-detection contract

16 November 2022

Kromek Group plc

("Kromek" or the "Group")

Kromek awarded £5m biological threat-detection contract by UK Government Department

Three-year contract awarded for development and supply of bio-detection system

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that it has secured a contract with a UK Government department to develop and supply biological threat detection systems.

Under the terms of the contract, Kromek will commence work in December for a three-year programme worth £4.9m. The contract also includes an option for extended maintenance services after the initial term.

Arnab Basu, CEO of Kromek Group, said: "We are delighted to have been awarded this contract to develop and supply an important capability for biological threat detection. The pandemic has demonstrated the impact of biological incidents - whether it is through an act of terror or naturally emerging threats. Governments throughout the world are reviewing their strategies to update their defence against such threats. We believe technologies that can provide information about emerging threats in near real time will be a critical component of such strategies."

For further information, please contact:
Kromek Group plc
Arnab Basu, CEO	[phone]
Paul Farquhar, CFO
finnCap Ltd (Nominated Adviser and Broker)
Geoff Nash/Seamus Fricker/George Dollemore - Corporate Finance	[phone]
Tim Redfern/Charlotte Sutcliffe - ECM
Gracechurch Group (Financial PR)
Harry Chathli, Claire Norbury	[phone]

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

Further information is available at www.kromek.com.